INEYE Therapeutics
INEYE Therapeutics develops InEye, a small ocular device patients insert themselves for eye treatment.
INEYE Therapeutics develops InEye, a small ocular device patients insert themselves for eye treatment.
ineyetherapeutics.comCrawled Oct 15, 2026
InEye is a mixture of drugs and polymers whose structure and composition can be adjusted to tune drug release for different diseases or treatments.
The roadmap includes pre-clinical testing of InEye placebo on pets to assess the technology’s safety, suitability and tolerability for veterinary use.
INEYE THERAPEUTICS secured a €600,000 investment round, including €250,000 from Portugal Ventures and an investment from Insight Venture. Portugal Ventures had previously invested €100,000 in 2023 through the INNOV-ID Call program.
Members of Ineye Therapeutics’ R&D team co-authored an article on eco-friendly synthesis of PCL-co-PEG copolymers, published in Discover Materials in 2025.
João Correia Neves, Secretary of State for the Portuguese Ministry of Economy, and Nuno Mangas, president of IAPMEI, visited the company’s laboratories.
INEYE THERAPEUTICS was founded on September 5, 2017, by biochemists Marcos Mariz and Paula Ferreira, its CEO and CSO. The founders had worked on biomaterials projects for more than two decades.
The company lists its headquarters and R&D laboratory addresses in Coimbra, Portugal, along with a phone number and email address.
The company’s mission is to develop medical devices and pharmaceutical products to improve quality of life. InEye combines drugs and polymers to tune drug release for different diseases and treatments.
The website collects comment form data, visitors’ IP addresses and browser user-agent strings to help detect spam.